4 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Tuberculosis, MDR: new trials by email Literature Review of Tuberculosis, MDR trials Research Report on Tuberculosis, MDR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 | Completed | Global Alliance for TB Drug Development | 26 | 2021-09-16 | 2025-01-17 |
| Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Control group, ASA group, IBU group - Tuberculosis, Pulmonary, Tuberculosis, MDR | Phase 2 | Terminated | Fundació Institut Germans Trias i Pujol | 426 | 2021-03-04 | 2026-06-01 |
| Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6) - Tuberculosis, MDR | Phase 3 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 5832 | 2019-06-03 | 2025-06-15 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 3 | Completed | Global Alliance for TB Drug Development | 181 | 2017-11-21 | 2023-06-29 |
| FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis FS-1, Placebo - Tuberculosis, MDR | Phase 3 | Completed | Scientific Center for Anti-infectious Drugs, Kazakhstan | 344 | 2013-12-01 | 2022-05-24 |
Tuberculosis (7) · Tuberculosis, Multidrug-Resistant (7) · Tuberculosis, Pulmonary (5) · Extensively Drug-Resistant Tuberculosis (2) · Communicable Diseases (1) · Latent Tuberculosis (1)
Actinomycetales Infections (7) · Bacterial Infections (7) · Bacterial Infections and Mycoses (7) · Gram-Positive Bacterial Infections (7) · Infections (7) · Mycobacterium Infections (7) · Lung Diseases (5) · Respiratory Tract Diseases (5) · Respiratory Tract Infections (5) · Disease Attributes (1) · Latent Infection (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
bedaquiline (4) · pretomanid (4) · Moxifloxacin (3) · Isoniazid (2) · Linezolid (2) · Pyrazinamide (2) · Aspirin (1) · Control Groups (1) · Ethambutol (1) · Ibuprofen (1) · OPC-67683 (1) · Pyridoxine (1) · Rifampin (1) · Vitamin B 6 (1)
Global Alliance for TB Drug Development (3) · Fundació Institut Germans Trias i Pujol (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Scientific Center for Anti-infectious Drugs, Kazakhstan (1) · University of California, San Francisco (1)
South Africa (5) · Georgia (4) · Uganda (3) · Brazil (2) · Peru (2) · Philippines (2) · Russia (2) · Tanzania (2) · Vietnam (2) · Botswana (1) · Haiti (1) · India (1) · Kazakhstan (1) · Kenya (1) · Kyrgyzstan (1)
Amirkan A Azembayev, Cond.Phar.Sc. (1) · Amita Gupta, MD, MHS (1) · Anneke Hesseling, MD, PhD (1) · Antonio Lombardi, MD (1) · Cristina Vilaplana, MD, PhD (1) · Francesca Conradie (1) · Gavin Churchyard, MBBCh MMed FRCP FCP(SA) PhD (1) · Morounfolu Olugbosi, MD MSc (1) · Susan Swindells, MBBS (1)